Stock Analysis
Charles River Laboratories International, Inc.CRL
Sector: Healthcare · Industry: Services-Commercial Physical & Biological Research
AnalystsStrong Buy23 analystsPrice is 93% of the way from the year's low to its high.
Cash covers 6% of debt · Q2 2026.
PMP Verdict
Weak fundamentals, expensive
Strengths
- Quality65
Risks
- Valuation40
- Growth6
Weak fundamentals at a demanding price.
What's happening with CRL
Profile
growth, profitability, valuation, moat and financial health lag behind.
How is each axis scored?
- Valuation40/100 · Weak
- P/E vs own history (n/a)10/25
- FCF yield (2.6%)5/25
- P/S (3.6x)20/25
- EV/EBIT (30.5x)5/25
- Growth6/100 · Weak
- Revenue CAGR (3.2%)6/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (n/a)0/25
- Profitability17/100 · Weak
- ROIC (7.8%)5/25
- ROE (-8.3%)0/25
- Net margin (-6.0%)0/25
- Operating margin (14.1%)12/25
- Financial Health45/100 · Weak
- Altman Z (2.57)18/25
- Current ratio (1.35)12/25
- Interest coverage (3.6x)10/25
- Net cash / debt (D/A 38%)5/25
- Quality65/100 · Moderate
- Piotroski F (6/9)15/25
- Beneish M (-3.07)25/25
- FCF conversion (n/a)0/25
- Margin stability (σ 2.5%)25/25
- Moat43/100 · Weak
- ROIC >12% years (0/10 yrs)0/25
- Median gross margin (36.8%)13/25
- FCF-positive years (10/10 yrs)25/25
- Worst-year net margin (worst -3.6%)5/25
About Charles River Laboratories International, Inc.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. Show more
The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provide in vitro (nonanimal) testing products, biologics testing services, and avian vaccine services.
Headquarters: WILMINGTON, MA · Employees: 19,700 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
40D+P/E (TTM)—
Price / TTM EPS (own statements)
P/FCF37.8xC
Grade C: ExpensivePrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield2.6%C
Grade C: LowTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 1.6%–11.1% · 14th pct
P/S (TTM)3.58xB
Grade B: FairPrice / TTM Revenue (own statements) — vs own 5Y history: 1.3x–7.9x · 87th pct
EV/EBIT30.5xD
Grade D: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 16.7x–164.1x · 68th pct
EV/Sales4.3xB
Grade B: FairEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E26.4xC
Grade C: ExpensivePrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio4.96xC
Grade C: ExpensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio-0.24A
Grade A: CheapFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
17EROIC7.8%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE-8.3%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA-3.2%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin-6.0%D
Grade D: LowNet Income / Revenue
Operating Margin14.1%C
Grade C: AverageTTM EBIT / TTM Revenue
Gross Margin27.8%D
Grade D: LowGross Profit / Revenue
FCF Margin9.3%C
Grade C: AverageFCF / Revenue
True FCF Margin7.2%C
Grade C: AverageTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
6ERevenue CAGR3.2%D
Grade D: LowCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth—
Analyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)-6.8%A
Grade A: BuybacksShare count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue2.1%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
45D+Altman Z-Score2.57C
Grade C: Gray zoneBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio1.35xC
Grade C: OkCurrent Assets/Liabilities
Quick Ratio0.83xC
Grade C: Ok(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage3.6xC
Grade C: OkEBIT/Interest. >10 Strong
Debt Repayment7.7yC
Grade C: AverageYears to repay net debt via FCF
Net Debt/EBIT5.1xD
Grade D: HighLeverage. <2x Low, >4x High
Debt/Equity1.05xC
Grade C: MedDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.06xD
Grade D: ThinCash covers how much of total debt. >1 = could repay all debt from cash
Quality
65BPiotroski F-Score6/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-3.07A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability2.5%A
Grade A: StableEBIT margin std deviation. Lower = stable
Capex / Revenue5.3%C
Grade C: AverageTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.53xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Parisotto Shannon M Filed | Parisotto Shannon M | Option exercise | -981 | |
Parisotto Shannon M Filed | Parisotto Shannon M | SellOpen market sale | -981 | |
Parisotto Shannon M Filed | Parisotto Shannon M | Option exercise | +981 | |
Coleman Glenn Filed | Coleman Glenn | BuyOpen market buy | +10 | |
FOSTER JAMES C Filed | FOSTER JAMES C | Option exercise | -12429 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
FOSTER JAMES C Filed | FOSTER JAMES C | Option exercise | -21132 | |
FOSTER JAMES C Filed | FOSTER JAMES C | SellOpen market sale | -33561 | |
FOSTER JAMES C Filed | FOSTER JAMES C | Option exercise | +12.4K |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
43D+ROIC >12% Years0/10 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)36.8%C
Grade C: ModerateMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor-3.6%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)—
TTM net income per share (Finnhub fallback)
Cash / Share$4.02
Cash & short-term investments per share (Finnhub)
Book Value / Share$59.50
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$3.03B
Total debt obligations (short + long term)
Cash & Equiv.$192.03M
Cash and short-term investments
Net Debt$2.84B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$2.89B
Shareholders' equity (book value)
Asset / Liability1.62xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$14.33B
Current Market Capitalization
Beta1.38C
Grade C: VolatilePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Charles River Laboratories International, Inc. (CRL)
CRL is down 1.99% at the last close. Piotroski F-Score of 6/9 indicates mixed fundamentals for Charles River Laboratories International, Inc.. Altman Z-Score of 2.57 falls in the grey zone (1.81–2.99) — financial distress is unlikely but not ruled out.
- Beneish M-Score of -3.07 suggests a low likelihood of earnings manipulation.
- Takes ~7.7 years to repay net debt from free cash flow.
- Charles River Laboratories International, Inc. posted a net loss in 1 of 10 available completed fiscal years (2016–2025).
See how CRL ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all CRL moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 5 | Regular | 308.57 | +6.33% | 2.80 |
| Oct 5 | After-hours | 310.77 | +7.09% | 3.12 |
| Sep 24 | Regular | 295.54 | +6.57% | 3.67 |
| Sep 24 | After-hours | 296.00 | +6.73% | 3.76 |
Frequently Asked Questions about CRL
What is the current Charles River Laboratories International, Inc. (CRL) stock price?
CRL is trading at $300.15 at the last market close, down 1.99% on the session. PreMarketPrice tracks CRL pre-market, intraday and after-hours prices.
Is CRL stock a buy right now?
PreMarketPrice's quantitative model rates Charles River Laboratories International, Inc.'s financial health at 45/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is CRL stock overvalued?
Charles River Laboratories International, Inc. trades at a trailing P/E of n/a and our valuation score rates it 40/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Charles River Laboratories International, Inc. report earnings?
No confirmed earnings date is currently scheduled for CRL. The Earnings section lists recent reports and updates as dates are announced.
What sector does Charles River Laboratories International, Inc. operate in?
Charles River Laboratories International, Inc. operates in the Healthcare sector, within the Services-Commercial Physical & Biological Research industry. The Related Stocks section lists sector peers for comparison.
What does Charles River Laboratories International, Inc. do?
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services.
About Charles River Laboratories International, Inc. (CRL) Stock
Charles River Laboratories International, Inc. (CRL) is a US-listed stock operating in the Healthcare sector, specifically the Services-Commercial Physical & Biological Research industry. As of the latest update, Charles River Laboratories International, Inc. is trading at $300.15, down 1.99% on the day with a market capitalization of $14.3 billion. The financial health score for CRL is 45/100, which indicates moderate financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for CRL stock.
CRL Stock Analysis & Key Metrics
On PreMarketPrice, you can track Charles River Laboratories International, Inc. (CRL) across multiple dimensions:
- Pre-market price & movement: Real-time CRL stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for CRL with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Charles River Laboratories International, Inc. across multiple reporting periods.
- Financial health score: A composite score of 45/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for CRL.
- Sector peers: Compare CRL against 6 other healthcare stocks on key financial metrics.
Is CRL a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Charles River Laboratories International, Inc. (CRL) as an investment. The financial health score of 45/100 suggests moderate financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Charles River Laboratories International, Inc. (CRL) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.